Related Experiment Videos
Improving Clinical Trials for Anticomplement Therapies in Complement-Mediated Glomerulopathies: Report of a
Andrew S Bomback1, Gerald B Appel2, Debbie S Gipson3
1Division of Nephrology, Columbia University Irving Medical Center, New York.
Abstract:
Blocking the complement system as a therapeutic strategy has been proposed for numerous glomerular diseases but presents myriad questions and challenges, not the least of which is demonstrating efficacy and safety. In light of these potential issues and because there are an increasing number of anticomplement therapy trials either planned or under way, the National Kidney Foundation facilitated an all-virtual scientific workshop entitled "Improving Clinical Trials for Anti-Complement Therapies in Complement-Mediated Glomerulopathies." Attended by patient representatives and experts in glomerular diseases, complement physiology, and clinical trial design, the aim of this workshop was to develop standards applicable for designing and conducting clinical trials for anticomplement therapies across a wide spectrum of complement-mediated glomerulopathies. Discussions focused on study design, participant risk assessment and mitigation, laboratory measurements and biomarkers to support these studies, and identification of optimal outcome measures to detect benefit, specifically for trials in complement-mediated diseases. This report summarizes the discussions from this workshop and outlines consensus recommendations.
Insights
Clinical trials for anti-complement therapies in glomerulopathies face challenges. This workshop developed standards for designing effective and safe clinical trials for these complement-mediated kidney diseases.
Area of Science:
- Nephrology
- Immunology
- Clinical Trial Design
Background:
- Complement system blockade is a potential therapy for glomerular diseases.
- Numerous anti-complement therapy trials are planned or underway, necessitating standardized trial design.
- Demonstrating efficacy and safety of anti-complement therapies presents significant challenges.
Framework:
- The National Kidney Foundation convened a workshop on improving clinical trials for anti-complement therapies in complement-mediated glomerulopathies.
- Experts and patient representatives collaborated to establish applicable standards for trial design and conduct.
- Focus areas included study design, risk assessment, laboratory measurements, biomarkers, and outcome measures.
Implementation:
- Consensus recommendations were developed for designing and conducting clinical trials.
- Standards aim to address the complexities of anti-complement therapies in various glomerulopathies.
- The goal is to ensure robust evaluation of therapeutic benefit and safety.
Implications:
- Standardized trial designs will facilitate more reliable assessment of anti-complement therapies.
- Improved clinical trial methodologies will accelerate the development of effective treatments for complement-mediated glomerulopathies.
- These recommendations will guide future research and clinical practice in this field.